SSG
TSHA icon

Summit Securities Group’s Taysha Gene Therapies TSHA Stock Holding History

Summit Securities Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-424
Closed -$1K – 896
2024
Q3 		$1K Buy
+424
New +$930 ﹤0.01% 523

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Securities Group's TSHA Position: Q4 2024 in Review

Summit Securities Group sold out of Taysha Gene Therapies (TSHA) in Q4 2024, closing a stake of 424 shares — an estimated $1K sold.

Summit Securities Group first reported a position in TSHA in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 131 funds tracked by Wall St. Rank hold TSHA as of Q4 2024.

  • Summit Securities Group reported no remaining Taysha Gene Therapies position as of Q4 2024 after selling out during the quarter.
  • Summit Securities Group sold 424 Taysha Gene Therapies shares in Q4 2024, an estimated $1K.
  • Summit Securities Group first reported a position in Taysha Gene Therapies in Q3 2024 and held it in 1 quarter.
  • Summit Securities Group's Taysha Gene Therapies position peaked at $1K in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2024.

Based on Summit Securities Group's 13F filing for Q4 2024, filed 12 Feb 2025.